Axsome Therapeutics Inc.
NASDAQ · AXSM·New York, NY·Mid-cap·Approved
CNS-focused company with Auvelity (dextromethorphan-bupropion) approved for major depressive disorder and Sunosi for excessive daytime sleepiness. Axsome's pipeline targets migraine, Alzheimer's agitation, and other neuropsychiatric conditions using novel oral mechanisms.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Axsome Therapeutics Corporate Presentation | Corporate overview | January 1, 2026 | 49 |